Benzinga | Mar 9, 2021 06:38PM EST

Alkermes Received FDA Orphan Drug Designation for fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha for Treatment of mucosal melanoma

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=806020